FrancophonIA/ELRC3.0 huggingface dataset:
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Estonian: Kombineeritud esmase tulemusnäitajaga (kardiovaskulaarne (CV) surm, MI, insult või refraktoorne isheemia) patsientide arv oli klopidogreeli rühmas 1035 (16,5%) ja platseeborühmas 1187 (18,8%), 14%-line suhtelise riski langusega (95% CI 6...21%; p=0,0005) klopidogreeli rühmas.
English: Discard any remaining tablets 30 days after first opening of the bottle.
Estonian: 30 tabletiga HDPE pudelid: Hävitada kõik alles jäänud tabletid 30 päeva pärast pudeli esmast avamist.
English: Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Estonian: Patsientidele manustati klopidogreeli (300 mg löökannus, seejärel 75 mg/päevas, n=1752) või platseebot (n=1739), mõlemat kombinatsioonis ASH-ga (löökannus 150…325 mg, seejärel 75…162 mg/päevas), fibrinolüütilise ravimi ja vajadusel hepariiniga.
English: Discard any remaining tablets 100 days after first opening of the bottle.
Estonian: 100 tabletiga HDPE pudelid: Hävitada kõik alles jäänud tabletid 100 päeva pärast pudeli esmast avamist.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg clopidogrel (as hydrobromide)
Estonian: TOIMEAINE(TE) SISALDUS Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesinikbromiidina)
English: If you forget to take a dose of Clopidogrel Teva Pharma B.V., but don't remember within 12 hours of the missed dose, skip the missed dose and take the next tablet at the usual time.
Estonian: annuse võtmata, kuid see ei meenu teile 12 tunni jooksul pärast vahelejäänud annust, jätke vahelejäänud annus võtmata ja võtke järgmine tablett tavalisel ajal.
English: If you forget to take Clopidogrel Teva Pharma B.V.
Estonian: Kui te unustate Clopidogrel Teva Pharma B.V.
English: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA) - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Estonian: ST segmendi elevatsioonita ägeda koronaarsündroomiga patsientidel (ebastabiilne stenokardia või Q-sakita müokardiinfarkt) kombinatsioonis atsetüülsalitsüülhappega (ASH), sealhulgas patsiendid, kellele paigaldatakse veresoonde võrktoru (koronaarstent) perkutaanse koronaarse interventsiooni käigus.
English: Clopidogrel should therefore be used with caution in this population (see section 4.2).
Estonian: Seetõttu tuleb selles patsiendigrupis klopidogreeli kasutada ettevaatusega (vt lõik 4.2).
English: No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Estonian: Inimestel ei ole klopidogreeli raviannusega täheldatud mõju metabolismis osalevate maksaensüümide aktiivsusele.
English: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co administered with atenolol, nifedipine, or both atenolol and nifedipine.
Estonian: Klopidogreeli samaaegsel manustamisel atenolooli, nifedipiini või nii atenolooli kui nifedipiiniga ei täheldatud kliiniliselt olulisi farmakodünaamilisi koostoimeid.
English: Do not take Clopidogrel Teva Pharma B.V.
Estonian: Ärge võtke Clopidogrel Teva Pharma B.V.
English: You should also be given acetylsalicylic acid (a substance used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Estonian: Arst võib teile määrata veel atsetüülsalitsüülhapet (seda ravimit kasutatakse valuvaigisti, palavikualandajana ning verehüüvete vältimiseks).
English: + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Estonian: Intrakraniaalseid verejookse oli klopidogreel + ASH grupis rohkem kui platseebo + ASH grupis (vastavalt 1,4% versus 0,8%).
English: • Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound
Estonian: • verevalumid, hematoom (ebatavaline nahaalune verejooks), ninaverejooks, mao või soolte verejooks, suurenenud veritsemine torkehaavast
English: What Clopidogrel Teva Pharma B.V. is and what it is used for What you need to know before you take Clopidogrel Teva Pharma B.V. How to take Clopidogrel Teva Pharma B.V.
Estonian: ja milleks seda kasutatakse Mida on vaja teada enne Clopidogrel Teva Pharma B.V.
English: Reduced levels of certain white blood cells which increases the risk of infection (neutropenia) Vertigo (dizziness accompanied by a whirling sensation) Bleeding inside the abdomen
Estonian: • teatud vere valgeliblede taseme langus, mis suurendab riski infektsiooni tekkeks (neutropeenia)
English: Driving and using machines Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery.
Estonian: ei mõjuta tõenäoliselt teie autojuhtimise või masinate käsitsemise võimet.
English: Rare side effects (may affect up to 1 in 1000 people):
Estonian: Harva esinevad kõrvaltoimed (võivad esineda kuni 1 inimesel 1000-st):
English: - Perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet.
Estonian: - Perforeeritud blistrid sisaldavad 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 või 100x1 õhukese polümeerikattega tablett.
English: - Peelable perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet.
Estonian: - Kooritavad perforeeritud blistrid sisaldavad 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 või 100x1 õhukese polümeerikattega tablett.
English: Clopidogrel Teva Pharma B.V. with food and drink You can take Clopidogrel Teva Pharma B.V. with or without food.
Estonian: koos toidu ja joogiga Te võite võtta Clopidogrel Teva Pharma B.V.
English: Ulcers in the stomach and small intestine, nausea, vomiting, constipation, flatulence (wind) and inflammation of the stomach leading to sickness, loss of appetite and discomfort after eating Reduction in blood platelets which makes bleeding or bruising more likely Blood disorders including a reduction in the number of white blood cells which makes infections more likely.
Estonian: • haavandid maos ja peensooles, iiveldus, oksendamine, kõhukinnisus, kõhupuhitus (gaasid) ja maopõletik, mis põhjustab iiveldust, söögiisu kaotust ja ebamugavustunnet söömise järel
English: The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).
Estonian: Klopidogreeli ja ASH kombinatsioonravist saadavat kasu üle neljanädalase kasutamise korral ei ole antud näidustusel uuritud
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Clopidogrel Teva Pharma B.V., 75 mg õhukese polümeerikattega tabletid
English: Prolonged bleeding, bleeding inside the head, bleeding in the eye, blood in the urine and/or purpura (red spots on the skin caused by bleeding underneath the skin) Rashes, itching, abnormal touch sensation
Estonian: • pikenenud veritsemine, koljusisene verejooks, silmasisene verejooks, veri uriinis ja/või purpur
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel oral use
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Clopidogrel Teva Pharma B.V., 75 mg õhukese polümeerikattega tabletid Klopidogreel
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel
Estonian: RAVIMPREPARAADI NIMETUS Clopidogrel Teva Pharma B.V., 75 mg õhukese polümeerikattega tabletid Klopidogreel
English: As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Pharma B.V.
Estonian: Ettevaatusabinõuna ei tohi Clopidogrel Teva Pharma B.V.
English: You should continue taking Clopidogrel Teva Pharma B.V. for as long as your doctor has told you to take it.
Estonian: võtmist nii kaua, kui teie arst on teil soovitanud seda võtta.
English: • Ticlopidine, other antiplatelet agent.
Estonian: • Tiklopidiini, teist trombotsüütide agregatsiooni vastast ravimit.
English: • Diarrhoea, abdominal pain, indigestion or heartburn
Estonian: • kõhulahtisus, kõhuvalu, seedehäire või kõrvetised
English: Common side effects (may affect up to 1 in 10 people):
Estonian: Sageli esinevad kõrvaltoimed (võivad esineda kuni 1 inimesel 10-st):
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets)
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA BLISTER- VÕI RIBAPAKENDIL BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 või 100x1 õhukese polümeerikattega tablett)
English: How to store Clopidogrel Teva Pharma B.V.
Estonian: Kuidas Clopidogrel Teva Pharma B.V.
English: How to take Clopidogrel Teva Pharma B.V.
Estonian: võtmist Kuidas Clopidogrel Teva Pharma B.V.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of peelable blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Kooritavate blistrite KARP (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 või 100x1 õhukese polümeerikattega tablett)
English: If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Pharma B.V.
Estonian: Hoiatused ja ettevaatusabinõud Rääkige oma arstile enne kui hakkate võtma Clopidogrel Teva Pharma B.V.
English: • Severe hepatic impairment.
Estonian: • veresoonte põletik, vererõhu langus
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Blistrite KARP (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 või 100x1 õhukese polümeerikattega tablett)
English: Clopidogrel Teva Pharma B.V. contains lactose.
Estonian: Clopidogrel Teva Pharma B.V.
English: Absorption
Estonian: võtmist
English: INFORMATION IN BRAILLE Clopidogrel Teva Pharma B.V. 75 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Clopidogrel Teva Pharma B.V.
English: Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide).
Estonian: Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli
English: Carefully peel off the backing
Estonian: Koorige ettevaatlikult ära kate.
English: E.g. abciximab,
Estonian: Deutschland ratiopharm GmbH
English: Film-coating
Estonian: Ninaverejooks
English: Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Manustamistee Vahetu sisepakend
English: RoActemra received a marketing authorisation valid throughout the EU on 16 January 2009.
Estonian: RoActemra on saanud müügiloa, mis kehtib kogu Euroopa Liidus, 16. jaanuaril 2009.
English: Further information on RoActemra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/RoActemra.
Estonian: Lisateave RoActemra kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/RoActemra.
English: What measures are being taken to ensure the safe and effective use of RoActemra?
Estonian: Mis meetmed võetakse, et tagada RoActemra ohutu ja efektiivne kasutamine?
English: RoActemra must not be used in patients who have an active, severe infection.
Estonian: RoActemrat ei tohi kasutada patsiendid, kellel on aktiivne raske infektsioon.
English: The European Medicines Agency decided that RoActemra's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et RoActemra kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib Euroopa Liidus heaks kiita.
English: All patients were also treated with a corticosteroid, which was stopped after reducing the dose gradually over 6 or 12 months.
Estonian: Kõik patsiendid said ka kortikosteroidravi, mis lõpetati pärast järkjärgulist annuse vähendamist 6 või 12 kuu jooksul.
English: Patients were allowed to continue treatment with methotrexate during the study.
Estonian: Patsiendid tohtisid jätkata uuringu ajal metotreksaadi kasutamist.
English: The pack will also include a patient alert card with key safety information for patients.
Estonian: Selles on ka patsiendi hoiatuskaart, kus on ohutuse põhiteave.
English: As for all medicines, data on the use of RoActemra are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse RoActemra kasutamise kohta pidevat järelevalvet.
English: Doctors should monitor patients carefully for signs of infection during treatment, and should prescribe RoActemra with caution in patients who have had recurring or long-term infections, or diseases that could increase the risk of infections, such as diverticulitis or diabetes.
Estonian: Arstid peavad patsiente ravi ajal hoolikalt jälgima infektsiooninähtude suhtes ja olema ettevaatlikud RoActemra määramisel patsientidele, kellel on korduvad või pikaajalised infektsioonid või haigused, mis võivad suurendada infektsiooni riski, näiteks divertikuliit või diabeet.
English: What is RoActemra and what is it used for?
Estonian: Mis on RoActemra ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of RoActemra have also been included in the summary of product characteristics and the package leaflet.
Estonian: RoActemra ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with RoActemra are carefully evaluated and any necessary action taken to protect patients.
Estonian: RoActemra kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: By preventing interleukin-6 attaching to its receptors, tocilizumab reduces the inflammation and other symptoms of these diseases.
Estonian: Interleukiin-6 seondumist retseptoritega takistades vähendab totsilisumaab põletikku ja teisi nende haiguste sümptomeid.
English: For more information about using RoActemra, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet RoActemra kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The most serious side effects are serious infections, complications of diverticulitis (a disease affecting the gut) and hypersensitivity (allergic) reactions.
Estonian: Kõige raskemad kõrvalnähud on rasked infektsioonid, divertikuliidi (teatud soolehaigus) tüsistused ja ülitundlikkusreaktsioonid (allergiareaktsioonid).
English: Other information about RoActemra:
Estonian: Muu teave RoActemra kohta
English: One of the studies, which involved 1,196 patients, also showed that the combination of RoActemra and methotrexate slowed down the damage to the joints and improved physical function after up to 2 years, when compared with the combination of placebo and methotrexate.
Estonian: Ühes uuringus (1196 patsienti) selgus ka, et RoActemra ja metotreksaadi kombinatsioon aeglustas liigeste kahjustumist ja parandas füüsilist aktiivsust kuni 2 aasta jooksul, võrreldes platseebo ja metotreksaadi kombinatsiooniga.
English: RoActemra is a medicine used to treat:
Estonian: RoActemra on ravim, mida kasutatakse järgmiste seisundite ravimiseks:
English: What are the risks associated with RoActemra?
Estonian: Mis riskid RoActemraga kaasnevad?
English: The most common side effects (occurring in up to 1 patient in 10) with RoActemra are upper respiratory tract infections (nose and throat infection), nasopharyngitis (inflammation of the nose and throat), headache, hypertension (high blood pressure) and abnormal liver function tests.
Estonian: RoActemra kõige sagedamad kõrvalnähud (esinevad enam kui 1 patsiendil 10st) on ülemiste hingamisteede infektsioonid (nina- ja kurgunakkused), nasofarüngiit (nina-neelupõletik), peavalu, hüpertensioon (kõrge vererõhk) ja maksatalitluse ebanormaalsed näitajad.
English: RoActemra can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of the relevant condition.
Estonian: RoActemra on retseptiravim ja ravi peab alustama vastava seisundi diagnoosimises ja ravis kogenud arst.
English: RoActemra (tocilizumab)
Estonian: RoActemra (totsilisumaab)
English: The company that markets RoActemra must supply all doctors expected to prescribe the medicine with an educational pack containing important information on the safety and correct use of RoActemra.
Estonian: RoActemra turustaja varustab kõik ravimit määravad arstid teabepakmega, mis sisaldab RoActemra ohutusteavet ja manustamisjuhiseid.
English: The main measure of effectiveness was based on the number of patients whose CRS resolved within 14 days of the first dose of RoActemra, and who needed no more than two doses of the medicine, and no additional treatment other than corticosteroid medicines.
Estonian: Efektiivsuse põhinäitaja tugines nende patsientide arvul, kelle tsütokiinide vabanemise sündroom paranes 14 päeva jooksul pärast RoActemra esmaannuse saamist, kes ei vajanud rohkem kui kaks ravimi annust ega muid lisaravimeid peale kortikosteroidide.
English: Studies show RoActemra is effective at reducing symptoms of several inflammatory conditions.
Estonian: Uuringutes on tõendatud, et RoActemra on efektiivne mitme põletikuhaiguse sümptomite vähendamisel.
English: Juvenile idiopathic polyarthritis
Estonian: Lapseea idiopaatiline polüartriit
English: Almost 4,000 patients from these 5 studies went on to enter studies looking at the long-term effects of RoActemra treatment and results showed that response to RoActemra is maintained for at least 2 years.
Estonian: Nendest 5 uuringust ligi 4000 patsienti jälgiti edasi jätku-uuringutes, milles vaadeldi RoActemra-ravi pikaajalist toimet.
English: How is RoActemra used?
Estonian: Kuidas RoActemrat kasutatakse?
English: For the full list of side effects of RoActemra, see the package leaflet.
Estonian: RoActemra kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Giant cell arteritis
Estonian: Hiidrakuline arteriit
English: One year after starting treatment, 56% of patients treated with RoActemra once a week did not have symptoms compared with 14% patients receiving placebo.
Estonian: Üks aasta pärast ravi alustamist olid sümptomiteta 56% kord nädalas RoActemrat saanud patsientidest ja 14% platseebot saanud patsientidest.
English: How does RoActemra work?
Estonian: Kuidas RoActemra toimib?
English: Juvenile idiopathic arthritis
Estonian: Lapseea idiopaatiline artriit
English: In the first study, RoActemra was more effective than placebo in treating rheumatoid arthritis: after 6 months of treatment with RoActemra, 61% of patients responded to treatment compared with 32% on placebo.
Estonian: Esimeses uuringus oli RoActemra reumatoidartriidi ravis efektiivsem kui platseebo: pärast 6-kuulist ravi oli ravivastusega patsiente RoActemra uuringurühmas 61% ja platseeborühmas 32%.
English: The fifth study involving 673 patients showed that patients receiving RoActemra on its own were more likely to respond than those taking methotrexate on its own.
Estonian: Viiendas uuringus (673 patsienti) selgus, et RoActemrat ainsa ravimina kasutanud patsientidel oli ravivastuse tekke tõenäosus suurem kui ainult metotreksaati kasutanutel.
English: • adults with severe rheumatoid arthritis that is getting worse in patients who have not been previously treated with a medicine called methotrexate;
Estonian: • raske süvenev reumatoidartriit täiskasvanutel, kes ei ole varem saanud metotreksaatravi;
English: This messenger is involved with inflammation and is found at high levels in patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis and CRS.
Estonian: See virgatsaine osaleb põletikuprotsessis ja selle sisaldus on suur patsientidel, kellel on reumatoidartriit, lapseea idiopaatilise artriidi süsteemne vorm, lapseea idiopaatiline polüartriit, hiidrakuline arteriit või tsütokiinide vabanemise sündroom.
English: RoActemra, on its own or in combination with methotrexate, was compared with placebo (a dummy treatment) plus methotrexate.
Estonian: Ainsa ravimina või koos metotreksaadiga manustatavat RoActemrat võrreldi koos metotreksaadiga manustatava platseeboga (näiv ravim).
English: In the fourth study, which included 498 patients who had an inadequate response to TNF blockers, patients receiving RoActemra with methotrexate were around 9 times more likely to respond than those receiving placebo with methotrexate.
Estonian: Neljandas uuringus (498 patsienti, kelle ravivastus TNF-i blokaatoritele oli ebapiisav) oli ravivastuse tekke tõenäosus RoActemra ja metotreksaadi kombinatsiooni uuringurühmas ligikaudu 9 korda suurem kui platseebo ja metotreksaadi rühmas.
English: The active substance in RoActemra, tocilizumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target (called an antigen) in the body.
Estonian: RoActemra toimeaine totsilisumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva teatud aine (antigeeni) ja seondub sellega.
English: The other study, which compared RoActemra injected under the skin with RoActemra given by infusion, showed that RoActemra injected under the skin was no less effective in achieving a response after 6 months.
Estonian: Teises uuringus võrreldi RoActemra subkutaanse süste ja RoActemra infusiooniga manustamist ning sellest selgus, et subkutaanse süstega manustatud RoActemra ei olnud vähem efektiivne ravivastuse saavutamisel 6 kuu järel.
English: Out of 51 patients who had CRS after being given the CAR-T cell medicine tisagenlecleucel, 39 responded to treatment with RoActemra (76.5%), while 8 out 15 patients (53.3%) who had CRS after being given axicabtagene ciloleucel responded.
Estonian: 51 patsiendist, kellel tekkis tsütokiinide vabanemise sündroom pärast CAR-T-rakkudel põhineva ravimi (tisageenlekleutseeli) manustamist, saavutas RoActemraga ravivastuse 39 (76,5%), ning 15 patsiendist, kellel tekkis tsütokiinide vabanemise sündroom pärast aksikabtageen-tsiloleutseeli manustamist, saavutas ravivastuse 8 (53,3%).
English: Another study involving 51 children from 1 year of age showed that RoActemra given by injection under the skin had a similar distribution in the body and effect on the disease to that previously seen with RoActemra given by infusion.
Estonian: Veel ühes uuringus, kus osales 51 vähemalt 1-aastast last, tõendati, et subkutaanse süstega manustatud RoActemra jaotus organismis samamoodi ja oli sama efektiivne kui infusiooniga manustatav RoActemra varasemas uuringus.
English: For the treatment of moderate to severe rheumatoid arthritis where other medicines were unsuccessful, RoActemra given by infusion was studied in five main studies involving a total of over 4,000 adults.
Estonian: Mõõduka kuni raske reumatoidartriidiga patsientidel, kellel ravi muude ravimitega oli ebaõnnestunud, uuriti infusiooniga manustatavat RoActemrat viies põhiuuringus, milles osales kokku üle 4000 täiskasvanu.
English: In systemic juvenile idiopathic arthritis, RoActemra given by infusion was compared with placebo in one main study involving 112 children in whom treatment with NSAID and corticosteroids did not work well enough.
Estonian: Lapseea idiopaatilise artriidi süsteemse vormi ravis võrreldi infusiooniga manustatavat RoActemrat platseeboga ühes põhiuuringus, milles osales 112 last, kelle ravivastus NSAID-ravimitele ja kortikosteroididele oli ebapiisav.